Clinical Trials Logo
  1. Home
  2. Severe Eosinophilic Asthma
  3. NCT03833141

Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab. — POWER  

Severe Eosinophilic Asthma Clinical Trial

Official title:
Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab.

Clinical Trial Summary

This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.

Clinical Trial Description

Benralizumab was launched in 2018 following regulatory approval in Canada and is now widely available for Canadian patients with severe eosinophilic asthma. This study is an observational cohort study of patient reported outcomes (PROs) within real-world settings for participants who are prescribed benralizumab for treatment of uncontrolled severe eosinophilic asthma. Patients will be recruited in select clinics across Canada. Survey data for each participant in the study will be obtained at the following time-points: - Baseline (Week 0) - Short-term follow up: 1-, 2-, 4-, and 8-weeks after baseline - Long-term follow-up: 24- and 56-weeks after baseline ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03833141
Study type Observational
Source AstraZeneca
Contact
Status Active, not recruiting
Phase
Start date November 12, 2018
Completion date May 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Completed NCT02560610 - Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Phase 2
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Not yet recruiting NCT03652376 - Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Phase 4
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Completed NCT05180357 - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Completed NCT05271526 - Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Not yet recruiting NCT06302959 - Clock Proteins as Prognostic Markers
Recruiting NCT05440656 - A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Completed NCT04159519 - A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Phase 4
Completed NCT03907137 - Real World Study With Benralizumab in Severe Asthma in Switzerland
Active, not recruiting NCT04084613 - Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
Completed NCT04126499 - Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Recruiting NCT06465485 - STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Phase 3
Recruiting NCT03739320 - A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma